NCT07158840View on ClinicalTrials.gov

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

June 30, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

AK112

AK112 Monotherapy

Trial Locations (1)

Unknown

Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT07158840 - AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment | Biotech Hunter | Biotech Hunter